Adage Capital Partners
OLMA icon

Adage Capital Partners’s Olema Pharmaceuticals OLMA Stock Holding History

Adage Capital Partners’s Portfolio OLMA Stock Details OLMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-275,000
Closed -$4.1M – 1061
2026
Q1 		$4.1M Buy
275,000
+65,000
+31% +$1.45M 0.01% 789
2025
Q4 		$5.25M Buy
+210,000
New +$3.74M 0.01% 757
2025
Q1 		– Sell
-365,198
Closed -$2.13M – 914
2024
Q4 		$2.13M Sell
365,198
-34,802
-9% -$348K ﹤0.01% 788
2024
Q3 		$4.78M Buy
400,000
+75,000
+23% +$959K 0.01% 719
2024
Q2 		$3.52M Sell
325,000
-135,000
-29% -$1.46M 0.01% 743
2024
Q1 		$5.21M Sell
460,000
-40,000
-8% -$516K 0.01% 695
2023
Q4 		$7.01M Buy
500,000
+111,018
+29% +$1.49M 0.01% 649
2023
Q3 		$4.8M Buy
388,982
+157,549
+68% +$1.61M 0.01% 666
2023
Q2 		$2.09M Sell
231,433
-188,567
-45% -$1.14M ﹤0.01% 739
2023
Q1 		$1.46M Hold
420,000
– – ﹤0.01% 785
2022
Q4 		$1.03M Hold
420,000
– – ﹤0.01% 840
2022
Q3 		$1.16M Sell
420,000
-80,000
-16% -$339K ﹤0.01% 884
2022
Q2 		$2.04M Buy
500,000
+411,203
+463% +$1.3M ﹤0.01% 878
2022
Q1 		$378K Buy
+88,797
New +$489K ﹤0.01% 966
2021
Q3 		– Sell
-225,000
Closed -$6.3M – 1051
2021
Q2 		$6.3M Buy
+225,000
New +$6.4M 0.01% 790

Other funds holding OLMA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Adage Capital Partners's OLMA Position: Q2 2026 in Review

Adage Capital Partners sold out of Olema Pharmaceuticals (OLMA) in Q2 2026, closing a stake of 275,000 shares — an estimated $4.1M sold.

Adage Capital Partners first reported a position in OLMA in Q2 2021 and held it in 15 quarters. The position peaked at $7.01M in Q4 2023. 185 funds tracked by Wall St. Rank hold OLMA as of Q2 2026.

  • Adage Capital Partners reported no remaining Olema Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Adage Capital Partners sold 275,000 Olema Pharmaceuticals shares in Q2 2026, an estimated $4.1M.
  • Adage Capital Partners first reported a position in Olema Pharmaceuticals in Q2 2021 and held it in 15 quarters.
  • Adage Capital Partners's Olema Pharmaceuticals position peaked at $7.01M in Q4 2023.
  • 185 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q2 2026.

Based on Adage Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.